SMTI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Sanara Medtech Inc. (SMTI) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has shown strong revenue growth and improvements in financial metrics, the lack of significant trading trends, news catalysts, and proprietary trading signals, combined with the absence of clear positive sentiment or valuation data, suggests a hold position for now.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 66.879, and moving averages are converging, showing no clear trend. The stock is trading near resistance levels (R2: 21.579) in pre-market at $21.07, suggesting limited immediate upside potential.
Gross margin improved to 90.56%, up 3.39% YoY. Positive MACD and bullish momentum.
Net income remains negative at -$30.41M despite significant YoY improvement. No recent news, trading trends, or congress trading data. RSI is neutral, and the stock is near resistance levels, limiting immediate upside.
In Q3 2025, revenue increased by 21.51% YoY to $26.33M. Net income improved significantly but remains negative at -$30.41M. EPS improved to -3.52, up 935.29% YoY. Gross margin increased to 90.56%, reflecting strong operational efficiency.
No data available for analyst ratings or price target changes.
